Abstract：
Cholangiocarcinoma is a highly morbid gastrointestinal malignancy for which available therapies are limited. Standard of care includes cytotoxic chemotherapies such as gemcitabine, platinum agents, nab-paclitaxel, and fluoropyrimidine analogues. However, tolerability of these regimens varies, and patients who do not tolerate chemotherapy have limited targeted therapies and immunotherapy options. In cholangiocarcinoma, mesenchymal-epithelial transition factor (MET) amplification may present an additional opportunity for a targeted therapeutic approach, especially considering emerging data in non-small cell lung cancer. In this case, we present a metastatic cholangiocarcinoma patient with high-level MET gene amplification for whom capmatinib, a tyrosine kinase inhibitor with activity against c-MET, provided a partial response after cessation of chemotherapy.
摘要：
胆管癌是一种高度病态的胃肠道恶性肿瘤，可用的治疗方法有限。护理标准包括细胞毒性化疗，如吉西他滨，铂剂,nab-紫杉醇,和氟嘧啶类似物.然而,这些方案的耐受性各不相同，不耐受化疗的患者的靶向治疗和免疫治疗选择有限.在胆管癌中，间充质上皮转化因子（MET）扩增可能为靶向治疗方法提供额外的机会，特别是考虑到非小细胞肺癌的新数据。在这种情况下,我们介绍了一名具有高水平MET基因扩增的转移性胆管癌患者，一种具有抗c-MET活性的酪氨酸激酶抑制剂，在化疗停止后提供了部分反应。
